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SUMMARY 
Introduction: Tuberculosis (TB), the second leading cause of death among infectious diseases continues to be 
a major public health threat worldwide, more so in the developing world. Several strategies have been tried 
in the past decades to address the burden of the disease especially in low resource settings; namely: Directly 
Observed Therapy Short-course (DOTS), DOTS plus, and the Stop TB Strategy. Amid all these efforts, 
tuberculosis has developed multi-drug resistant strains (MDR) to various degrees and is now listed amongst 
the top re-emerging diseases in the world. The objectives of this study were to find out trend in TB case 
detection; age/sex distribution, new smear positive cases, identify the major type of TB, treatment outcomes, 
within the five-year period reviewed. 
Methods: In this cross-sectional records review of years 2011-2015, secondary data was extracted from 
tuberculosis central registers at all sites in Delta State, Nigeria. The data was using win PEPI and EPIDATA 
software solutions and presented in tables and charts. 
Results: There was a decline in case detection from 2011 to 2015, ages 25–34 years, was the largest proportion, 
while ages 0–4 years was the smallest proportion. Although males were generally more than females, the 
proportion of females was higher between ages 15-44. Treatment success rate improved from 68.7% in 2011 
to 88.0 % in 2014. The sputum AFB positive rate was less than 60% for the first four years but spiked to 
above 70% in 2015. A decline in the proportion of patients lost to follow-up was observed from 2011 to 2015.  
Conclusion: The Delta State Tuberculosis programme improved in case-holding. There is therefore a need 
for renewed public enlightenment and other strategies to improve patient compliance with the stipulations of 
the national tuberculosis control program. 
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Introduction  
Mycobacterium Tuberculosis infection is a major 
infectious cause of deaths globally, mostly in 
developing countries.[1] It is a debilitating disease 
with a greater prevalence and severity in a background 
of reduced immunity. In more recent years, it has 
become even more complex due to a rise in its drug-
resistant strains, among other issues.[2] 
It is still the second leading cause of death among the 
infectious diseases and continues to be a major public 
health threat worldwide. Several tuberculosis control 
strategies were formulated through the mid-20th to the 
21st century; namely: DOTS, DOTS plus and the Stop 
TB strategy intended to address the burden of the 
disease.[3,4] 
Amid all the efforts to control TB, the tide is not 
abating; instead it is reappearing in almost epidemic 
proportions and now listed amongst the top re-
emerging diseases, mainly because of increasing 
multidrug resistance and co-infection with HIV/AIDS. 
Till date, no other disease in history matches the sheer 
magnitude of the misery inflicted by TB on the human 
race in terms of morbidity and mortality. [5] 
In a developing country like Nigeria, tuberculosis is 
one of the top public health problems almost 
everywhere, ranking fourth among the 30 high-burden 
TB countries in the world. [5]  There were 90,447 TB 
cases notified in 2010 with 41,416 (58%) as new 
smear positive cases, and a case detection rate of 40% 
in Nigeria.[6] Although targets were set to reverse the 
incidence, half the prevalence and mortality, diagnose 
70 percent  of new smear-positive cases and cure 85 
percent  of tuberculosis cases by 2015, for many 
countries, these targets were not achieved despite the 
current existence of interventions.[7,8] New TB cases 
were estimated to be 10.6 million globally in 2016, 
with 1.4 million deaths and an additional 0.4 million 
deaths among the people co-infected with human 
immunodeficiency virus; 95 percent of these occurred 
in developing countries.[9] 
The policy of the national programme in Nigeria is for 
all patients to be treated free of charge using DOTS 
strategy for six months in pulmonary TB cases, and 
twelve months for TB meningitis and spine. In many 
developing countries including Nigeria, Direct 
Sputum Smear Microscopy (SSM) is the most widely 
used test for the diagnosis of pulmonary tuberculosis 
in accordance with the International Standards on 
Tuberculosis Care.[10,11] 
The implementation of DOTS, which has been long 
established in Nigeria, is practised through sites 
distributed in the various states of the country. This 
study therefore aimed to provide a summary 
description of patients who received DOTS for 
tuberculosis in Delta State, Nigeria in terms of 
prevalence of tuberculosis, age/sex distribution, new 
smear positive cases, identification of the major type 
of TB seen, and to assess treatment outcomes 
including cure rates, failure, loss to follow up (LTFU) 
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and death rates among tuberculosis patients managed 
at DOTS centres over a five–year period. 
Methods 
Secondary data from January, 2011 through 
December, 2015 from all ninety-eight TB-DOTS sites 
in the 3 senatorial zones of Delta State were collected 
and analysed in a cross-sectional records review to 
identify trends. Data was extracted from a 
standardized and updated State Tuberculosis Central 
Registry using a validated proforma and reanalysed 
using Microsoft Excel, winPEPI and Epidata software 
solutions. The results were represented using 
frequency tables and charts.  
 
Results 
The total number of TB patients seen at DOTS clinics 
in Delta State in the past five years is 13,635. Although 
there would have been overlaps, there was a consistent 
decline in numbers from 2011 to 2015. The total 
number in 2011 was 3076 while the total number in 
2015 was 2349. The rate of decline slowed down 
between 2014 and 2015. Each year, age group 25–34 
years made up the highest proportion of patients 
presenting for treatment at DOTS clinics while ages 
0–4 years was the smallest proportion. Although the 
proportion of male patients was consistently more than 
that of females, for the ages 15-44 years, the collective 
proportion of females was consistently higher than 
that of males for all the years reviewed. (Table 1)
Table 1: Age/sex distribution of TB patients at DOTS centres in Delta State
 
 
                                                                          Sex of patients   Frequency (%)                                                                         
Age  
group 
2011 2012 2013 2014 2015 
M F M F M F M F M F 
0-4 24(1.3) 16(1.3) 15(0.9) 14(1.1) 18(1.1) 18(1.5) 15(1.1) 13(1.30 8(0.6) 5(0.5) 
5-14 38(2.1) 39(3.2) 43(2.5) 64(5.1) 32(2.0) 48(4.0) 22(1.6) 28(2.8) 33(2.4) 31(3.3) 
15-24 220(12.0) 228(18.5) 243(14.3) 214(17.0) 222(13.8) 222(18.1) 203(14.4) 188(18.9) 183(13.1) 198(20.9) 
25-34 517(28.0) 402(32.6) 425(25.0) 379(30.0) 395(24.5) 362(29.5) 351(24.9) 297(30.0) 279(21.2) 248(26.1) 
35-44 419(22.7) 246(20.0) 396(23.2) 282(22.3) 396(24.5) 252(20.5) 337(24.0) 221(22.3) 337(24.1) 221(23.3) 
45-54 290(15.7) 143(11.6) 265(15.6) 143(11.3) 264(16.4) 154(12.5) 227(16.1) 118(11.9) 270(19.3) 131(13.8) 
55-64 172(9.3) 88(7.1) 165(9.7) 91(7.2) 140(8.7) 89(7.2) 133(9.4) 60(6.0) 161(11.5) 59(6.2) 
≥65 164(8.9) 70(5.7) 152(9.0) 75(6.0) 146(9.1) 83(6.7) 122(8.7) 68(6.8) 129(9.2) 56(5.9) 
Sub-
total 
1844(60) 1232(40) 1704(57.5) 1262(42.5) 1613(56.8) 1228(48.2) 1410(58.7) 993(41.3) 1400(59.6) 949(40.4) 
Total      3076(100)       2966(100)       2841(100)       2403(100)          2349(100) 
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Each year, age group 25–34 years made up the modal 
age group of new smear positive cases presenting at 
DOTS clinics while ages 0–4 years made up the 
smallest proportion. The next highest 
frequencies/proportions were seen in age groups 35-
44 years, and 15-24 years. Males were consistently 
more in the 35-44 years age group than in the 15-24 
years group throughout the 5 years reviewed but 
females were more in age group 15-24 years than in 
the 35-44 years group for years 2011, 2013 and 2015. 
In 2012 and 2014, females aged 15-24 years were at 
par with ages 35-44 years. (Table 2) 
 
Table 2: Age/Sex Distribution of New Smear Positive Cases from 2011 - 2015 
 
There was a consistent decline in the total number of 
TB cases seen in each year for the 5 years reviewed 
but the number and proportion of AFB positive cases 
fluctuated during the years in review. The proportion  
 
of AFB positive cases detected among TB patients was 
consistently less than 60% for years 2011 through 
2014; but in 2015 the proportion of AFB+ cases 
detected increased steeply to over 70% (Figure 1) 
 
 
Sex of patients 
Frequency (%) 
 2011 2012 2013 2014 2015 
Age  
Group 
M F M F M F M F M F 
0-4 1(0.1) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 2(0.20 0(0) 
5-14 9(1.0) 21(3.4) 13(1.3) 20(3.0) 8(1.0) 13(2.0) 11(1.4) 10(1.8) 14(1.4) 16(2.4) 
15-24 147(15.1) 163(26.3) 175(17.3) 148(22.5) 132(14.9) 158(24.4) 136(17.0) 121(22.2) 143(14.3) 160(24.2) 
25-34 307(31.6) 219(35.3) 282(27.8) 215(32.6) 260(29.3) 204(31.5) 209(26.1) 181(33.2) 225(22.6) 189(28.5) 
35-44 231(23.7) 120(19.4) 258(25.4) 154(23.4) 229(25.8) 137(21.2) 205(25.6) 121(22.2) 253(25.4) 154(23.3) 
45-54 155(16.0) 54(8.7) 158(15.6) 63(9.6) 134(15.1) 72(11.1) 121(15.1) 62(11.4) 192(19.3) 76(11.5) 
55-64 68(7.0) 23(3.7) 72(7.1) 32(4.9) 72(8.1) 37(5.7) 68(8.5) 28(5.1) 103(10.3) 35(5.3) 
≥65 55(5.6) 20(3.2) 56(5.5) 27(4.1) 53(5.9) 26(4.0) 51(6.3) 23(4.2) 66(6.6) 32(4.8) 
Sub-
total 
973(61.1) 620(38.9) 1014(60.6) 659(39.4) 888(57.9) 647(42.1) 801(59.5) 546(40.5) 997(60.1) 662(39.9) 
Total     1593 (100)      1673 (100)       1535 (100)       1347 (100)        1659 (100) 
                                                                                 
88 
African Journal of Health Sciences, Volume 31, Number 1, January-March 2018 
 
AFB+/N Ratio (%) 51.8 56.4 54.0 56.1 70.6 
N refers to the total number of tuberculosis patients seen each year consecutively for the 5 years reviewed 
Figure 1: Comparison of total no. of tuberculosis patients with no. of AFB+ Cases 
The proportion of new tuberculosis patients notified 
each year was generally on the increase from 2011 
through 2015 although 2012 was an exception. This 
implies that the cases of relapse, treatment failures, 
and return after loss to follow-up were generally on the 
decline through the years. The newly registered cases 
were 85.5% in 2011 and gradually rose to 97.8% in 
2015 except for 2012 when newly registered cases 
constituted 93.9% which was higher than the newly 
registered cases in 2013. (Figure 2) 
 
 
Figure 2: Categories of patients registered for TB-DOTS treatment in Delta State 
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The relative proportion of PTB and EPTB that 
presented at DOTS centres in Delta State was nearly 
constant for the 5 years reviewed. Extra pulmonary TB 
was about 2% of patients for all the years with a small 
variation in 2013. (Figure 3) 
 
 
 
 
 
 
 
 
 
 
Figure 3: Proportions of Pulmonary and Extra-pulmonary Tuberculosis at DOTS Clinics 
 
Figure 4: Trends in treatment outcomes of tuberculosis patients in Delta State 
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The treatment completion rate fluctuated between 
32.7% and 43.2% between 2011 and 2015. Cure rate 
for patients ranged from 35.6% to 45.4%; it was 
highest in 2014. Loss to follow-up rate was 
disproportionately high in 2011 at 25% compared to 
the other years – all of which were below 10%. Death 
rate was similar for the 5 years reviewed; it ranged 
from 4.3% to 5.4%. 
Discussion 
The control of tuberculosis continues to be topical as 
the burden and complexity of the disease is still a 
source of much concern both globally and locally. 
This study of TB patients in Delta State has shown a 
steady decline in the total number of TB patients seen 
at DOTS centres over the 5 years reviewed. It is not 
immediately obvious why this is so but this finding is 
consistent with that of a similar study in United States, 
and it is not surprising as control efforts have been 
consistent in the last decade. [12] 
Sex distribution in this study was similar to that from 
a previous study conducted within the state13 and in 
other studies in western and eastern Nigeria where the 
prevalence of tuberculosis amongst males was 
generally greater than that of females.[14–16] This 
finding is also consonant with that from studies from 
outside Nigeria where male predominance has been 
observed.[17,18] However, the findings contradict the 
assertion that prevalence of tuberculosis is higher in 
females in countries like Nigeria where the prevalence 
of HIV is above 1%.[19] The reason for this 
dissimilarity is not clear especially as the prevalence 
of HIV in Nigeria is 3.2% and 4.1% in Delta State.[20] 
However, a closer observation reveals that although 
the total number of male patients was more than that 
of females for each year, for ages 15-44 years, the 
collective proportion of females was consistently 
greater than that of males for the 5 years reviewed. 
This is more consistent with the WHO assertion of a 
female preponderance in high burden HIV 
countries.19 This could truly be the effect of HIV and 
due to the fact that transgenerational sex and marriage 
are somewhat common in this environment.[21,22] 
The patients who presented for treatment at DOTS 
centres were mostly new TB cases ranging between 
85.5% and 97.8%; a finding similar to that from a 
study at Nnewi, Anambra state where the rate of new 
cases was 80.8%.[23]Belete et al also showed a similar 
percentage of new cases in a study on treatment 
outcome of tuberculosis patients under directly 
observed treatment in Addis Ababa, Ethiopia.[24] The 
loss to follow-up rate in this review was mostly around 
5% and similar to studies which revealed a loss to 
follow-up rate of 3%,16 but less than 8.93% reported 
in another study conducted in south-west.[25] These 
findings were however a far cry from the loss to 
follow-up rates of 18.3% and 15.7%  reported from 
previous studies conducted in Nigeria and 
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India.[23,26] Though there was an improvement in 
loss to follow-up rates within the last year reviewed in 
this study, it could be attributed to the patient’s 
knowledge and beliefs about their illness, motivation 
to manage it, and awareness of consequences of poor 
adherence all interacting to influence adherence 
behaviour. However, loss to follow-up rate in 2011, 
was disproportionately higher than for the rest of the 
years. This could have been to the introduction of 
tracking of patients that were lost to follow-up. This 
was introduced in the programme in the year 2010 and 
continued till 2015. This suggests that extra effort by 
the DOTS providers to track loss to follow-up 
significantly reduced this programmatic challenge and 
case-holding in Delta State.  
The decline in TB cases as well as the trend of AFB 
positive cases over the five years was unlike findings 
from a similar study in Enugu state which showed a 
rising trend of TB cases despite a decline in the 
proportion of AFB positive cases.[14] AFB positive 
cases in this study were disproportionately higher in 
2015 and did not align with the decreasing trend. This 
may have been due to the recent introduction of Xpert 
MTB Rif in the diagnosis of TB. The findings of this 
study with respect to sex and age patterns of sputum 
smear positive PTB correlate with reports from a 
recent study in southern Nigeria,[27]and are consistent 
with the documented global epidemiology of the 
disease.28 
A predominance of pulmonary tuberculosis, as seen in 
this study (98%), was also reported by studies of 
patients treated at DOTS centres in South-Western 
Nigeria, Eastern Nigeria, and Europe where 94.8%, 
97%, 86.5% and 80.3% of the patients had pulmonary 
tuberculosis.[23,25,29] Hospital wide infectious 
disease profiles have shown PTB to be quite common 
in a couple of settings: A review in North-West 
Ethiopia saw a prevalence of 43.8%; Kano, Nigeria 
with a prevalence of 14.7%, and Saudi Arabia with a 
prevalence of 10.3%.[30–32] These findings show 
that the burden of tuberculosis is still high in a lot of 
settings – especially in settings like ours or may be due 
to over diagnosis of PTB due to a greater use of chest 
X-ray reports, case definitions and clinical findings 
instead of the standard AFB or Xpert MTB Rif tests. 
Extra-pulmonary tuberculosis was more prevalent in 
other studies in Ibadan, Oyo state, and Nnewi, 
Anambra State, Nigeria and another study in Europe 
with a prevalence of 15.6%, 13.5% and 19.3% 
respectively,23,29,33 than in this review where only 
2% had EPTB within the five years reviewed. The 
reason for this could be over diagnosis or higher co-
infection with HIV in those studies. A higher 
prevalence of 51.2% and 56.2% of EPTB, have been 
recorded in studies in north-west Ethiopia.[31,34]The 
reasons for this are not immediately obvious. 
This study revealed that over a period of five years, the 
proportion of patients who had completed their TB 
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treatment gradually increased from 32.7% to 43.2%. 
This finding was in contrast to a study conducted in 
Southern Ethiopia where there was a decline in the 
proportion of patients who completed TB treatment 
from 68% to 50 % over a period of ten years.[35] The 
cure rate for patients in this review fluctuated between 
35.6% and 45.4% which was rather inconsistent and 
low compared to the WHO recommended TB cure rate 
of 85%. [36] However, this corroborated findings 
from a study conducted in Eku, Delta State, Nigeria 
where the cure rate was 45.7%.[13] This finding is 
probably a result of the inconsistencies in the system 
of provision of DOTS services in Delta State. These 
inconsistencies could include drug stock-outs; lack of, 
or poor follow-up services and reminder systems, and 
possibly, inconsistencies with timing of clinics. 
Several studies from India, Pakistan, Iraq and Mexico 
reported varying cure rates; 42.9%, 55%, 63.5%, 
69.6% and 82.7% respectively.[18,37–40] Though 
there was an improvement in the treatment success 
rate observed in this study. 
The loss to follow-up rate of patients attending DOTS 
clinics observed in this study, steadily declined from 
25% to 4.3% for the first four years. However, there 
was a slight increase to 6.1% after one year.  This 
finding was mostly lower than values obtained from 
Eku, Delta State where loss to follow-up rate was 
observed to be 12.9% over a five-year period. The 
reason for this difference could be attributed to the fact 
that the study conducted in Eku assessed only one 
DOTS centre compared to this study that assessed 
twenty-six centres in Delta State. However, results 
from this study were worse compared to those 
observed in North-West Ethiopia where loss to follow-
up rate among TB patients was reportedly low at 
2.5%.[35]  The differences observed between these 
studies may be from challenges observed in the 
delivery of general health care services, including 
DOTS in Nigeria. 
The treatment failure rate in this study was below 3% 
for the years reviewed and similar to 2.7% reported 
from a previous study conducted by Echendu et al in 
eastern, Nigeria.[23] This suggests that TB drug 
resistance may be low in Delta State even though it is 
among the high burden States for TB in Nigeria.[41] 
The death rate among TB patients observed in this 
study ranged from 4.3% to 5.4%. These rates were 
similar to those from studies conducted in Abuja, 
Nigeria and Felige, Ethiopia where death was reported 
to be 4.9% and 5.8% respectively. [31,42] Slightly 
lower mortality rates of 3%, 2.7%, and 3.6% recorded 
from previous studies in Mexico and India indicate a 
likely generally better outcome of treatment for 
patients in those countries.[39,40,43]However, this 
finding were in contrast to reports from a study in 
Saudi Arabia where TB mortality rate was 
18%.[32]Although death rate in this study was 
markedly lower than that compared to the Saudi 
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Arabian study, the probable reason for this could be 
because more than half of the patients in the Saudi 
study had associated co-morbidities. It also needs to 
be kept in mind that the treatment outcomes of patients 
who loss to follow-up are unknown. 
Conclusion 
Tuberculosis is common in all age groups in Delta 
State but most prevalent in the second and third 
decades of life. Its prevalence has been on the decline 
since 2011 in Delta State. Extra- pulmonary 
Tuberculosis rate has been stable at about 2%. 
Treatment outcomes in Delta State do not meet the 
WHO recommendations 
References 
1.  Jeon C, Murray M. Diabetes mellitus increases 
the risk of active tuberculosis: A systematic 
review of 13 observational studies. PLoS Med. 
2008;5:e152. 
2.  Ohkado A, Aguiman L, Adlawan S, et al. 
Tuberculosis drug resistance and treatment 
outcomes under DOTS settings in large cities in 
the Philippines. Int J Tuberc Lung Dis. 
2006;10(3):283-289. 
3.  Balasubramanian VN, Oommen K, Samuel R. 
DOT or not? Direct observation of anti-
tuberculosis treatment and patient outcomes, 
Kerala State, India. Int J Tuberc Lung Dis. 
2000;4(5):409-413. 
http://www.ncbi.nlm.nih.gov/pubmed/1081573. 
4.  Ukwaja KN, Alobu I, Ifebunandu NA, Osakwe 
CP. Trends in treatment outcome of smear-
positive pulmonary tuberculosis in Southeastern 
Nigeria , 1999 - 2008. Ital Ian J Public Heal. 
2012;9(4):1-7. doi:10.2427/8660. 
5.  World Health Organization. Global 
Tuberculosis Report 2015. Geneva; 2015. 
6.  United States embassy in Nigeria. Nigerian 
Tuberculosis Factsheet.; 2012. 
7.  Baltussen R, Floyd K, Dye C. Achieving the 
millennium development goals for healthCost 
effectiveness analysis of strategies for 
tuberculosis control in developing countries. 
BMJ. 2005:1-6. 
8.  Raviglione MC UM. WHO’s new Stop TB 
Strategy. Lancet. 2000;367(9514):952-955. 
9.  World Health Organization (WHO). World 
Tuberculosis Report 2016. Geneva; 2016. 
10.  Juyal D, Thaledi S. Same day sputum 
microscopy: Optimizing the diagnosis of 
pulmonarytuberculosis. OA Case Reports. 
2014;3(3):25. 
11.  Davis JL, Cattamanchi A, Hopewell PC, 
Steingart KR. Are front‐loaded strategies 
comparable to standard strategies for diagnosing 
pulmonary tuberculosis by sputum smear 
microscopy? A systematic review and meta-
analysis. 
hppts://www.stoptb.org/assest/document on. 
                                                                                 
94 
African Journal of Health Sciences, Volume 31, Number 1, January-March 2018 
Accessed September 21, 2016. 
12.  Center for Disease Control (CDC). Reported 
Tuberculosis in United States. Atlanta, GA: U.S 
Department of Health and Human Services.; 
2014. Available at 
http;//www.cdc.gov/tb/statistics/reports/2014. 
13.  Onorikpori TO. To Review the Prevalence and 
Treatment Outcome of Pulmonary Tuberculosis 
in the TB Referral Hospital Eku, Delta State 
(January 2009 to December 2013). 
14.  Dim, CC, Dim N. Trends of tuberculosis 
prevalence and treatmentoutcome in an under- 
resourced setting. The case of Enugu state, south 
eastNigeria. Niger Med J. 2013;54:392-397. 
15.  Egbewale BE, Taiwo SS, Odu OO, Olowu OA, 
Sobaloju SO. Tuberculosis Treatment Outcomes 
in State Hospital Oshogbo, South-western 
Nigeria: afour-yearreview. Niger J Med. 
2007;16(2):148-155. 
16.  Omotosho BA, Adebayo AM, Adeniyi BO, 
Ayodeji OO, Ilesanmi OS, Kareem AO  et al. 
Tuberculosis Treatment Outcomes and 
Interruption among Patients Assessing DOTS 
Regimen in a Tertiary Hospital in Semi-Urban 
Area of South-Western Nigeria. Niger J Med. 
2014;23(1):51-56. 
17.  Motghare DD, Sardessai GM, Vaz FS, Kulkarni 
MS. Study of treatment outcomes in tuberculosis 
patients on DOTS therapy at five centres in Goa. 
Int J Community Med Public Heal. 
2014;1(1):48-51. doi:10.5455/2394-
6040.ijcmph20141110. 
18.  Santha T, Garg R, Frieden T, et al. Risk factors 
associated with default, failure and death among 
tuberculosis patients treated in a DOTS 
programme in Tiruvallur District, South India, 
2000. Int J Tuberc Lung Dis. 2002;6(9):780-
788. 
19.  World Health Organization (WHO). Global 
Tuberculosis Control, Epidemiology, Strategy, 
Financing: WHO Report. Geneva; 2009. 
20.  National Population Commission (NPC) 
[Nigeria] and ICF International. Nigeria 
Demographic and Health Survey 2013. Abuja, 
Nigeria, and Rockville, Maryland, USA: NPC 
and ICF International; 2014. 
http//:www.population.gov.ng/ndhs-data. 
21.  Luke N. Age and economic assymetries in the 
sexual relationships of adolescent girls in sub-
saharan Africa. Stud Fam Panning. 
2003;34(2):67-86. 
22.  Adedokun O, Adeyemi O, Dauda C. Child 
marriage and maternal health risks among young 
mothers in Gombi , Adamawa State , Nigeria : 
implications for mortality , entitlements and 
freedoms . Afr Health Sci. 2016;16(4):986-999. 
23.  Echendu DA, Victor AM, Emmanuel CA, 
Ifeoma CI, Darlington CO. Characterization of 
Defaulters from Tuberculosis Treatment in a 
Tertiary Hospital in South Eastern Nigeria. Open 
                                                                                 
95 
African Journal of Health Sciences, Volume 31, Number 1, January-March 2018 
J Epidemiol. 2016;6:1-9. 
24.  Getahun B, Ameni G, Medhin G, Biadgilign S. 
Treatment Outcome of Tuberculosis Patients 
under Directly Observed Treatment in Addis 
Ababa, Ethiopia. Brazilian J Infect Dis. 
2013;17:521-528. 
25.  Atif M, Sulaiman SA, Shafie AA, Ali I, Asif M, 
Babar ZU. Treatment Outcome of New Smear 
Positive Pulmonary Tuberculosis Patients in 
Penang, Malaysia. BMC Infect Dis. 
2014;14:399. 
26.  Karanjekar VD, Lokare PO, Gaikwad AV, 
Doibale MK, Gujrathi VV, Kulkarni AP. 
Treatment Outcome and Follow-Up of 
Tuberculosis Patients Put on Directly Observed 
Treatment Short-Course under Rural Health 
Training Center, Paithan, Aurangabad in India. 
Ann Med Health Sci Res. 2014;4:222-226. 
27.  Dye C,Hosseini M WC. Did we reach the 2005 
targets for tuberculosis control? Bull World Heal 
Organ. 2007;85(5):364-369. 
28.  Dye C, Davies PD, Barries PF GS. Clinical 
Tuberculosis. 4th editio. London, hodder & 
Stoughton limited; 2008. 
29.  Sandgren AH, Vander-werf MJ. Extra-
pulmonary Tuberculosis in the European union 
and European economic area. Euro surveillancy. 
2013;18(2):431. 
30.  TS Imam, TI Oyeyi. A retrospective study of 
Pulmonary Tuberculosis (PTB) prevalence 
amongst patients attending infectious diseases 
hospital in Kano , Nigeria. Bajopas. 
2008;1(1):10-15. 
31.  Biadglegne F, Tesfaye W, Anagaw B, Tessema 
B, Debebe T, Anagaw B, Rodloff AC. 
Tuberculosis Lymphadenitis in Ethiopia. Jpn J 
Infect Dis. 2013;66.:263-268. 
32.  Bukhary ZA, Alrajhi AA. Tuberculosis 
treatment outcome in a tertiary care setting. Ann 
Saudi Med. 2007;27(3):171-174. 
33.  Salami AK, Oluboyo PO. Health care workers 
and risk of hospital-related tuberculosis. Niger J 
Clin Pract. 2013;11(1):32-36. 
34.  Gebreegziabher SB, Yimer SA BG. 
Tuberculosis case notification and Treatment 
outcome in west gojjam zone North West 
Ethiopia. J Tuberc Res. 2016;4:23-33. 
35.  Dangisso MH, Datiko DG, Lindtjorn, B. Trend 
of tuberculosis case notification and treatment 
outcome in Sidama zone, Southern Ethiopia. 
2014. 
36.  Federal Ministry of Health. National 
Tuberculosis , Leprosy and Buruli Ulcer 
Management and Control Guidelines. 6th ed. 
Abuja: Federal Ministry of Health, Nigeria; 
2015. 
37.  Fulath A-RM, Kareem GM, Abdullah OA. 
Assessment Treatment Outcomes of Directly 
Observed Treatment Short Course Programme 
among Tuberculosis Patients in Al-Najaf 
                                                                                 
96 
African Journal of Health Sciences, Volume 31, Number 1, January-March 2018 
Governorate, Iraq. J US-China Med Sci. 
2015;12(3):120-126. doi:10.17265/1548-
6648/2015.03.005. 
38.  Ponce-de-leon A, Garcia-Garcia ML, Garcia-
Sancho ML, Gomez-Perez FJ, Valdespino-
Gomez JL, Olaiz-Fernandez G  et al. 
Tuberculosis and Diabetes in Southern Mexico. 
Diabetes Care. 2004;7:1584 – 1590. 
39.  Padda P, Gupta V, Devgan S, Chaudhary S, 
Singh G. Treatment outcome of TB patients in a 
district of north India: A three year study. Nepal 
J Epidemiol. 2015;5(1):457-461. 
40.  Walley DW, Khan MA, Newell JN, Khan MH. 
Effectiveness of the direct observation 
component of DOTS for tuberculosis:a 
randomized controlled trial in Pakistan.Lancet 
2001. 357AD;99(257):664-669. 
41.  Akenzua O. Delta Creates 81 Centres for 
Diagnosis, Treatment of TB.; 2017. 
42.  Jamda MA, Lawson L, Nnodu OO, Ajani MN, 
Umobong EO, Frederick, CC, et al. Treatment 
outcome of patients Co-infected with 
tuberculosis and HIV in Abuja, Nigeria. Niger J 
Basic Clin Sci. 11(2):72-75. 
43.  Godlwana L, Gounden P, Ngubo P, Nsibande, 
Nyawo K, Puckree T. Incidence and profile of 
spinal tuberculosis in patients at the only public 
hospital admitting such patients in KwaZulu-
Natal. Spinal Cord. 2008;8(46):372-374. 
 
 
 
